Introduction {#Sec1}
============

Lung cancer is the leading cause of cancer death within the United States (Siegel et al., [@CR1]). The TNM staging system developed by the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) is the primary means for classifying patient disease status and predicting patient prognosis, with the most recent 8^th^ edition recently introduced by the International Association for the Study of Lung Cancer (IASLC) (Detterbeck et al., [@CR2]; Asamura et al., [@CR3]; Rami-Porta et al., [@CR4]; Goldstraw et al., [@CR5]). Stage 3B Non-small Cell Lung Cancer (NSCLC) now comprises patients without distant metastases (M0) who have stage T3 or T4 primary disease, with ipsilateral mediastinal and/or subcarinal nodal metastases (N2), as well as patients with T1 or T2 primary disease with metastases in scalene, supraclavicular, contralateral mediastinal or contralateral hilar lymph nodes (N3). In other words, Stage 3B encompasses a wide range of primary tumor burden, including patients with primary tumors ranging from \<1 cm (T1a) to ≥7 cm (T4) in greatest dimension and N0 to N3 nodal metastases.

For patients with locally advanced lung cancer, fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) enables detection of CT-occult, metabolically active tumor. Maximum standardized uptake value (SUVmax) is an established measurement of maximal tumor metabolic activity and facilitates identification of tumor metastases, but it fails to take into account total tumor abundance/burden. Quantitative FDG measurements, namely the amount of whole body metabolic tumor volume (MTVwb) and total lesion glycolysis (TLGwb), may be used to quantify both total tumor burden and metabolic activity. These parameters have been found to be associated with OS for both surgical and non-surgical NSCLC patients, after adjusting for clinical stage (Liao et al., [@CR6]; Zhang et al., [@CR7]; Zhang et al., [@CR8]). These PET/CT metrics have yet to be evaluated for Stage 3B NSCLC patients (Ohri et al., [@CR9]).

Patients with Stage 3B NSCLC are rarely surgical candidates due to mediastinal invasion or extensive nodal disease, and are routinely treated with combined radiation and chemotherapy, though options are constantly evolving to cater to a more individualized patient-centered therapeutic approach (Rocco et al., [@CR10]). The overall survival (OS) of Stage 3B NSCLC patients at 2 and 5 years is 44% and 26%, respectively (Goldstraw et al., [@CR5]). If we can identify additional prognostic markers for these patients, we may be able to better stratify Stage 3B NSCLC patients, and determine who is more likely to benefit from more aggressive therapy.

Here we aimed to evaluate the prognostic value of MTVwb, TLGwb, and SUVmaxwb, on baseline FDG PET/CT in patients with Stage 3B NSCLC.

Materials and methods {#Sec2}
=====================

This Health Insurance Portability and Accountability Act compliant retrospective study received institutional review board approval. The need for informed consent was waived.

Patient cohort {#Sec3}
--------------

Utilizing a retrospective search of our health information system, patients were included if they met both of the following inclusion criteria: a. diagnosed with Stage 3B NSCLC in accordance with the 8^th^ edition of the TNM classification system; and b. received baseline staging PET/CT between February 2004 and Dec 2014. Patients were excluded if they either: 1. received prior lung cancer treatment, including chemotherapy, radiation, or surgery; or 2. had a second primary cancer diagnosed from 5 years before to 2 months after the FDG PET/CT scan conducted for NSCLC diagnosis and staging. 110 consecutive patients were identified from center A and served as the training set. The external validation set included 44 patients managed and imaged at institution B from 2008 to 2014. These patients received a FDG PET/CT within 3 months of starting radiation therapy.

Patient demographics, clinical information, and follow-up were collected from the health information system. Patients were censored at date of last contact.

PET/CT acquisition {#Sec4}
------------------

Imaging was performed on a Siemens mCT scanner (Siemens Healthcare, Knoxville, Tenn) or Reveal HD scanner (CTI, Knoxville, Tenn). All patients fasted for a minimum of 4 h prior to imaging, confirmed by fingerstick serum blood glucose levels \<200 mg/dl. Patients were injected with 370-555 MBq ^18^F--FDG. At center A (the training dataset), whole body PET/CT imaging was acquired approximately 90 min later. At center B (the validation dataset), patients were scanned approximately 60 min later. Concomitant low-dose non-contrast or diagnostic CT extending from the skull base to thighs was performed for anatomic localization and attenuation correction.

PET/CT tumor volume, SUVmaxwb, MTVwb, and TLGwb were measured using the PET Edge tool of MIMvista software as illustrated in Fig. [1](#Fig1){ref-type="fig"}, using semi-automated tumor segmentation, as previously described (Liao et al., [@CR6]).Fig. 1Whole-body PET images of a 59 year-old male with newly diagnosed squamous cell carcinoma, stage IIIB (T4N2M0). This study was performed for initial staging. Colored regions of interest (ROIs) show the tumor contours. The MTVwb in mL is the sum of tumor volumes in all ROIs. Axial image (**a**), sagittal image (**b**), coronal image (**c**) and maximal intensity projection image (**d**)
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                \begin{document}$$ \frac{\mathrm{decayed}\  \mathrm{corrected}\  \mathrm{activity}/\mathrm{tissue}\  \mathrm{volume}}{\mathrm{injected}\  \mathrm{dose}/\mathrm{injected}\  \mathrm{weight}} $$\end{document}$. SUVmaxwb was taken to be the largest SUVmax among all tumor lesions identified on baseline staging PET/CT. MTVwb was defined as the total segmented volume of all FDG-avid tumors in the body. TLG for a single tumor lesion is the product of MTV and the average SUV for the lesion. TLGwb was calculated as the sum of the TLGs of all segmented tumor.

Statistical analysis {#Sec5}
--------------------

Statistical analyses were performed using Stata Software version 14. OS was considered the primary endpoint and defined as the time from baseline PET/CT to time of any cause mortality. Analysis was conducted using natural-logarithm transformed values of the PET parameters \[(ln(MTVwb), ln(TLGwb), and ln(SUVmaxwb)\] in order to achieve a near-normal distribution of independent variables. Univariate and multivariate analyses were performed with Cox proportional hazard regression models to test for an association with the primary end point, OS. *P*-value of \<0.05 from a two-tailed test was considered significant. Survival curves were plotted using the Kaplan-Meier method.

Results {#Sec6}
=======

Model fitting {#Sec7}
-------------

The model was fitted using the training dataset of 110 patients with Stage 3B NSCLC (41% adenocarcinoma; 32% squamous cell; 27% other histologic sub-type) who met the inclusion criteria, with patient characteristics summarized in Table [1](#Tab1){ref-type="table"}. The median patient age was 67.3 (range 31.4--83.9) years. There were 47 Caucasian patients, 60 African American patients and 3 Asian patients. The majority of patients (69%) were managed non-surgically (with chemotherapy and/or radiation), while 22% received surgical treatment, and 9% did not treatment. 86/110 patients expired during follow-up. The median OS was 14 months. 1-year, 2-year, and 5-year OS was 56.5%, 34.6% and 13.9%, respectively. The median follow-up among survivors was 26.0 months (inter-quartile range 13.6 to 57.1 months).Table 1Characteristics of patients from the University of ChicagoClinical and PET ParametersNumber of patientsPercentageGender Male4743% Female6357%Race Caucasian4743% African American6055% Asian33%Treatment Surgically2422% Non-surgically7669% None109%Histological subtype Adenocarcinoma4541% Squamous cell3532% Other types^a^3027%Age (Median and range, years)67.3(31.4--83.9) \>654440% \<656660%MTVwb (Median and range, ml)85.6(3.2--1261.4)TLGwb (Median and range, ml)485.5(12.1--4921.0)SUVmaxwb (Median and range)13.07(3.5--42.9)*MTVwb* whole-body metabolic tumor volume, *SUVmaxwb* whole-body maximum standardized uptake value, *TLGwb* whole-body total lesion glycolysis^a^Other histological subtypes including large cell (*n* = 7), NSCLC not otherwise specified (*n* = 21) and neuroendocrine tumor (*n* = 2)

Univariate Cox regression analysis showed no significant difference in OS on the basis of age, gender, or histology (Table [2](#Tab2){ref-type="table"}). Surgical treatment (24/110 patients) was associated with improved OS, as compared to the no treatment and non-surgical treatment groups. Some of the PET/CT variables, ln(TLG~WB~) and ln(SUV~WB~), were not associated with OS.Table 2Univariate Cox regression analysesHazard ratio95% CI*P*-valueAge (per 1 year increase)1.020 .99 -1.0340.171Gender FemaleReference Male1.190.78--1.830.419Histology AdenocarcinomaReference Squamous1.370.83--2.260.218 other types1.330.78 2.270.303Treatment Non-surgical (*n* = 76)Reference Surgical (*n* = 24)0.40.22 -0.710.002 No treatment (*n* = 10)0.990.47 -2.10.986ln(MTV~wb~)1.231.01--1.490.037ln(TLG~wb~)1.130.95--1.340.175In(SUVmaxwb)0.910.57--1.430.67Note: ln(MTVwb), ln(TLGwb) and ln(SUVmaxwb) are continuous variables. ln = natural logarithmic transformation

However, ln(MTVwb) was positively associated with OS, with a hazard ratio (HR) of 1.23 with 95% confidence interval (95% CI) of 1.01--1.49, (*p* = 0.037). This association persisted on multivariate Cox regression analysis with a HR of 1.28 (95% CI =1.01--1.64, *p* = 0.043), after adjustment for age, gender, treatment and tumor histology (Table [3](#Tab3){ref-type="table"}).Table 3Multivariate Cox regression analyses of whole cohortVariablesHazard ratio95% CI*P*-valueln(MTVwb)1.281.01--1.640.043Treatment Non-surgicalReference Surgical0.410.22--0.760.004 No treatment1.340.59--3.020.48Additional adjustments were made for age, gender, treatment and tumor histology

The training dataset was segmented by the median MTVwb of 85.6 mL, Kaplan-Meier survival curves (Fig. [2](#Fig2){ref-type="fig"}) demonstrate decreased OS among patients with MTVwb greater than or equal to the median, when compared to those patients with MTVwb less than the median (*p* = 0.021). The median OS was 9.5 months in patients with MTVwb greater than or equal to the median, while the median OS was 17.3 months in patients with MTVwb less than the median.Fig. 2Kaplan-Meier overall survival curves of the training dataset of 110 patients with TNM Stage 3B NSCLC, stratified by the median MTVwb of 85.6 mL. The dashed line indicates patient group with MTVwb greater than or equal to 85.6 ml with median OS of 9.5 months. The solid line indicates patient group with MTVwb less than 85.6 ml with median OS of 17.3 months. The difference is statistically significant with *p* = 0.02

Model validation {#Sec8}
----------------

To validate the model, a separate analysis was performed using a dataset of 44 patients who were imaged and managed from medical center B. These 44 patients received radiation-based treatment. The median OS was 20 months and 1-year, 2-year, and 5-year OS was 60%, 45% and 38%, respectively. 24/44 patients (55%) expired during follow-up. The median follow-up among survivors was 30.7 months (inter-quartile range 12.7 o 49.1 months).

With a univariate Cox regression model, there was significant positive correlation of ln(MTVwb) with OS, HR of 1.83 (95% CI = 1.14--2.94, *p* = 0.012). For 7 of 44 patients, the SUVmax and TLGwb were not available due to missing accurate weight information during PET/CT acquisition. Univariate Cox regression analysis in the remaining 37 patients demonstrated no statistically significant association of ln(TLGwb) (HR = 1.37, 95% CI = 0.94--2.00, *p* = 0.1) and ln(SUVmaxwb) (HR = 1.30, 95% CI = 0.53--3.17, *p* = 0.57) with OS. After adjusting for tumor histology, there remained significant positive correlation with ln(MTVwb) and OS, with HR of 1.78 (95% CI = 1.01--2.90, *p* = 0.02). The results provided further evidence for the prognostic value of ln(MTVwb). Kaplan-Meier survival curves with groups defined by the median MTVwb from the training set (85.6 mL) further demonstrated significantly lower OS among patients with MTVwb ≥85.6 mL, when compared to those with MTVwb \<85.6 mL (*p* = 0.028; Fig. [3](#Fig3){ref-type="fig"}). The median OS was 13.9 months in patients MTVwb ≥85.6 mL. For patients with MTVwb \<85.6 mL, the median OS could not be determined because more than 50% of patients were alive at the last follow-up (median follow-up of 30.7 months).Fig. 3Kaplan-Meier overall survival curves of the validation dataset of 44 patients with TNM stage 3B NSCLC, stratified by the median MTVwb of the training dataset, 85.6 mL. The dashed line represents the patient group with MTVwb ≥85.6 ml with median OS of 13.9 months. The solid line represents the patient group with MTVwb \<85.6 ml with median OS not reached during follow-up period. The groups were significantly different with *p* = 0.03

Discussion {#Sec9}
==========

Quantitative PET/CT parameters are increasingly used to better stratify patients with cancer. Multiple studies have evaluated the association of primary tumor and whole body MTV, TLG, and SUVmax with respect to OS, though this has yet to be evaluated for Stage 3B NSCLC (8^th^ edition TNM classification) (Liao et al., [@CR6]; Zhang et al., [@CR7]; Zhang et al., [@CR8]; Ohri et al., [@CR9]; Liao et al., [@CR11]; Chung et al., [@CR12]; Im et al., [@CR13]; Hyun et al., [@CR14]; Hyun et al., [@CR15]; Carvalho et al., [@CR16]; Kim et al., [@CR17]; Abelson et al., [@CR18]; Satoh et al., [@CR19]; Winther-Larsen et al., [@CR20]; Yoo et al., [@CR21]; Zhu et al., [@CR22]; Vu et al., [@CR23]; Lee et al., [@CR24]). We sought to better delineate prognosis among patients with Stage 3B NSCLC by utilizing MTVwb, SUVmaxwb, and TLGwb.

Among patients with Stage 3B NSCLC, greater MTVwb was associated with shorter OS, independent of age, sex, and histology. This was further validated by an external dataset of 44 patients treated with radiation-based treatment at outside hospitals. Other studies have shown that OS significantly decreases with every 1 cm increase in primary tumor burden and with increasing number and extent of nodal metastases, which prompted recent changes to the TNM classification (Asamura et al., [@CR3]; Goldstraw et al., [@CR5]). Thus, it is not surprising that quantitative PET/CT measures of whole body tumor burden are similarly associated with OS.

Here we did not find a significant association between SUVmaxwb or TLGwb and OS in patients with Stage 3B NSCLC. SUVmaxwb is a maximum single voxel measurement, so it may not be representative of the entire disease process. Additionally, SUVmaxwb is not representative of the total extent of tumor burden. Though TLGwb incorporates MTVwb, it was not statistically significantly associated with OS in this sample of patients with Stage 3B NSCLC, despite the estimated HR of 1.13. The lack of statistical significance is most likely due to the small sample size in this study, as opposed to a true lack of association with survival.

Among the Stage 3B NSCLC patients in the training cohort, the 2-year and 5-year OS was 34.6% and 13.9%, lower than the survival observed in the IASLC database (44% and 26%, respectively) (Goldstraw et al., [@CR5]). However, our validation dataset had 2- and 5-year survival of 45%, 38%, which is more similar to the IASLC database. One explanation for the difference in OS may be related to socioeconomic status: Center A serves a predominantly low-income neighborhood, a factor that has been previously associated with worse OS (Aldrich et al., [@CR26]). Furthermore, the training dataset included 10 patients who had no treatment, which is likely to lower OS.

The training dataset had a significantly higher proportion of African American patients (55%) than other studies, like the 1996--2007 Florida Cancer Data System registry of 98,541 patients with NSCLC, which was only 7.4% African American (Tannenbaum et al., [@CR25]). Although our study included a disproportionate number of African Americans compared to both other registries and the national population, prior work by Aldrich et al., has shown that lung cancer survival is independent of race, when adjusting for stage and socioeconomic status (Aldrich et al., [@CR26]).

Limitations {#Sec10}
-----------

Due to the retrospective design of this study, it was not possible to control the type of surgery, chemotherapy or radiation that patients received. Treatment for each patient was determined at the discretion of the surgeon and oncologist and, ultimately, by the patient. In addition, PET/CT has limited sensitivity to detect lesions which are less than 1 cm in diameter or which have low metabolic uptake, likely resulting in a slight under measurement of MTVwb and TLGwb. Since patients in the validation dataset were exclusively treated with radiation-based treatment, and the significant association between OS and MTVwb persists, this strongly suggests the robust prognostic value of MTVwb.

In summary, among patients with Stage 3B NSCLC increasing MTVwb measured on baseline FDG PET/CT is associated with worse OS in both univariate and multivariate cox regression analysis, as seen in both the training and validation datasets. Currently, PET/CT volumetric parameters do not affect clinical management, but hopefully the developing knowledge regarding the values of these measurements may allow more targeted treatment for patients with more or less aggressive disease. Regardless, identifying which patients are more likely to survive to 2 or 5 years may be extremely valuable to patients, who may be planning the final months or years of their life.

Conclusion {#Sec11}
==========

MTVwb is a prognostic marker for OS in patients with Stage 3B NSCLC, independent of age, gender, treatment, and tumor histology.

AJCC

:   American Joint Committee on Cancer

CT

:   Computed tomography

FDG

:   2-deoxy-2-\[18F\]fluoro-D-glucose

HR

:   Hazard ratio

IASLC

:   International Association for the Study of Lung Cancer

MBq

:   Megabecquerel

MTVwb

:   Whole-body metabolic tumor volume

NSCLC

:   Non-small cell lung cancer

OS

:   Overall survival

PET

:   Positron emission tomography

SUVmaxwb

:   Maximum standardized uptake value

TLGwb

:   Whole body total lesion glycolysis

TNM

:   Tumor-node-metastases

UICC

:   Union for International Cancer Control

N/A

Funding {#FPar1}
=======

This work was supported in part by a grant (R21 CA181885) from the National Cancer Institute of the National Institutes of Health.

Availability of data and materials {#FPar2}
==================================

The data supporting the findings can be found in the corresponding author's institution.

Guarantors of integrity of entire study: BZD, F-MK and YP. Study concepts/study design or data acquisition or data analysis/interpretation: all authors; Manuscript drafting or manuscript revision for important intellectual content: all authors. Approval of final version of submitted manuscript: all authors; Agrees to ensure any questions related to the work are appropriately resolved by all authors; Literature research: BZD, F-MK and YP. Clinical studies: CZ, LX, HL, LY, YL, YP. Statistical analysis: YP and F-MK. Manuscript editing: all authors.

Ethics approval and consent to participate {#FPar3}
==========================================

This study was approved by our Institutional Review Board of the University of Chicago, which waived the requirement for informed consent and all methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication {#FPar4}
=======================

N/A

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
